Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IGD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: IGD. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2010-020904-31 Sponsor Protocol Number: CACZ885D2402 Start Date*: 2010-12-20
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio piloto, abierto, multicéntrico, de eficacia y seguridad del tratamiento con canakinumab durante 6 meses y seguimiento de hasta 6 meses, en pacientes con síndrome de Hiper-IgD activo.
    Medical condition: síndrome de Hiper-IgD activo
    Disease: Version SOC Term Classification Code Term Level
    13 10067539 IgD elevada LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001426-24 Sponsor Protocol Number: P02470 Start Date*: 2004-11-23
    Sponsor Name:Prof. Heinz Ludwig, MD, Wilhelminenspital, First Department of Medicine and Medical Oncology
    Full Title: Multicenter, open, randomized study for first-line treatment of multiple myeloma: thalidomide/dexamethasone vs. MP for induction therapy and thalidomide/Intron A vs. Intron A for maintenance therapy
    Medical condition: First line treatment of multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-020167-20 Sponsor Protocol Number: KB047 Start Date*: 2010-10-19
    Sponsor Name:KEDRION
    Full Title: Pharmacokinetics, efficacy, tolerability and safety evaluation of the therapy with subcutaneous immunoglobulin in the treatment of hypo or agammaglobulinaemic patients. Open label phase II/III study
    Medical condition: Hypogammaglobulinaemia or agammaglobulinaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060384 LLT
    9.1 10001471 LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005269-37 Sponsor Protocol Number: 836021009 Start Date*: 2014-10-02
    Sponsor Name:St. Antonius Hospital
    Full Title: RITUXIMAB IN LIFE THREATENING THERAPY RESISTANT PROGRESSIVE INTERSTITIAL PNEUMONITIS
    Medical condition: Patients with rare Immune mediated inflammatory diseases (IMIDs) involving the lungs causing interstitial pneumonitis (IP).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003631-36 Sponsor Protocol Number: RG_12-124 Start Date*: 2015-02-10
    Sponsor Name:University of Birmingham
    Full Title: CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL
    Medical condition: Chronic lymphocytic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10068852 B-cell chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-000026-31 Sponsor Protocol Number: ML18704 Start Date*: 2006-06-20
    Sponsor Name:Roche Austria GmbH
    Full Title: Bevacizumab as treatment for patients with relapsed/refractory multiple myeloma
    Medical condition: Multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007007-32 Sponsor Protocol Number: IGD 001 Start Date*: 2007-12-13
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
    Full Title: Efficacy of IVIG in the treatment of treatment-resistent painful neuropathy
    Medical condition: Painful Neuropathies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012680 Diabetic neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002054-55 Sponsor Protocol Number: PXD101-301-G Start Date*: 2006-01-12
    Sponsor Name:Topotarget A/S
    Full Title: A phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma
    Medical condition: Patients in relapse from prior treatment, with histologically and otherwise verified diagnosis of multiple myeloma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001327-23 Sponsor Protocol Number: ITP0815 Start Date*: 2015-06-26
    Sponsor Name:Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
    Full Title: Eltrombopag as Second line Therapy in adult patients with primary Immune Thrombocytopenia (ESTIT study) in an attempt to achieve long-term remission: a single arm multicenter phase II clinical and ...
    Medical condition: Primary Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020347-12 Sponsor Protocol Number: CA204004 Start Date*: 2011-06-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) BE (Completed) FR (Completed) CZ (Completed) DK (Completed) IE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) GR (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001865-41 Sponsor Protocol Number: CC-5013-MM-015 Start Date*: 2007-03-27
    Sponsor Name:Celgene International Sàrl
    Full Title: A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) FR (Completed) DE (Completed) IE (Completed) CZ (Completed) AT (Completed) GB (Completed) DK (Completed) SE (Completed) IT (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000665-36 Sponsor Protocol Number: 20180015 Start Date*: 2019-06-12
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) NL (Completed) ES (Ongoing) CZ (Completed) FR (Completed) BG (Completed) SK (Completed) FI (Completed) LT (Completed) AT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-004823-39 Sponsor Protocol Number: CC-5013-MM-020/IFM 07-01 Start Date*: 2008-04-03
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 FOUR-WEEK...
    Medical condition: Previously untreated multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) IE (Prematurely Ended) IT (Completed) AT (Completed) ES (Completed) SE (Completed) BE (Completed) PT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022445-20 Sponsor Protocol Number: CA204006 Start Date*: 2011-11-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma.
    Medical condition: Untreated Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) BE (Completed) AT (Completed) GR (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001842-34 Sponsor Protocol Number: DOXIL-MMY-3001 Start Date*: 2004-11-29
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development
    Full Title: A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
    Medical condition: Recurred or relapsed multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023483-41 Sponsor Protocol Number: I10E-0718 Start Date*: 2011-03-01
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: A MULTICENTER STUDY ON THE EFFICACY, SAFETY AND PHARMACOKINETICS OF I10E IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID)
    Medical condition: a primary immunodeficiency as defined by the ESID and validated by a reference centre : • X-linked agammaglobulinemia (XLA) • Common variable immunodeficiency (CVID)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10010112 Common variable immunodeficiency LLT
    14.1 100000004870 10036700 Primary immunodeficiency syndromes HLT
    14.1 100000004870 10001471 Agammaglobulinemia LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) Outside EU/EEA
    Trial results: Removed from public view
    EudraCT Number: 2012-000445-12 Sponsor Protocol Number: IPAR0001 Start Date*: 2012-07-17
    Sponsor Name:Department off Infectious Diseases, Aarhus University Hospital Skejby, Denmark
    Full Title: Immune Response to Bivalent or Quadrivalent Human Papilloma Virus vaccination in Patients with Chronic Renal Failure
    Medical condition: Cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10071147 Human papilloma virus immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001027-12 Sponsor Protocol Number: IsKPd-IFM2018-03 Start Date*: 2019-10-07
    Sponsor Name:CHU de Poitiers
    Full Title: Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003038-26 Sponsor Protocol Number: ARGX-113-1603 Start Date*: 2017-02-08
    Sponsor Name:Argenx BVBA
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia, followed by an Op...
    Medical condition: Primary Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10074678 Primary immune thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed) BE (Completed) DE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-001618-27 Sponsor Protocol Number: EMN14/54767414MMY3013 Start Date*: 2017-05-19
    Sponsor Name:Stichting European Myeloma Network (EMN)
    Full Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy Wi...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Ongoing) BE (Completed) DE (Completed) CZ (Completed) DK (Completed) FR (Completed) NL (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 03:32:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA